

Data Sharing Statement

Lin. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases. *JAMA Oncol.* Published December 01, 2022. doi:10.1001/jamaoncol.2022.5610

Data

Data available: Yes

Data types: Deidentified participant data

How to access data: All requests can be submitted to CTDR@seagen.com and will be reviewed by an internal review committee.

When available: With publication

Supporting Documents

Document types: None

Additional Information

Who can access the data: De-identified patient-level trial data that underlie the results reported in this publication will be made available on a case-by-case basis to researchers who provide a methodologically sound proposal.

Types of analyses: De-identified patient-level trial data that underlie the results reported in this publication will be made available on a case-by-case basis to researchers who provide a methodologically sound proposal.

Mechanisms of data availability: De-identified patient-level trial data that underlie the results reported in this publication will be made available on a case-by-case basis to researchers who provide a methodologically sound proposal.